References
- Berghea, F., Berghea, C. E., Zaharia, D., Trandafir, A. I., Nita, E. C., Vlad, V. M. (2021). Residual pain in the context of selecting and switching biologic therapy in inflammatory rheumatic diseases. Front. Med. (Lausanne), 8, 712645. DOI: 10.3389/fmed.2021.712645.10.3389/fmed.2021.712645841582634485342
- Black, R. J., Lester, S., Buchbinder, R., Barrett, C., Lassere, M., March, L., Whittle, S., Hill, C. L. (2017). Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: A drug use study from a prospective national biologics registry. Arthritis Res. Ther., 19 (1), 253.10.1186/s13075-017-1461-3568872429141677
- Bos, W. H., van Tubergen, A., Vonkeman, H. E. (2021). Telemedicine for patients with rheumatic and musculoskeletal diseases during the COVID-19 pandemic; a positive experience in the Netherlands. Rheumatol. Int., 41 (3), 565–573.10.1007/s00296-020-04771-6780963833449162
- D’Angelo, S., Carriero, A., Gilio, M., Ursini, F., Leccese, P., Palazzi, C. (2018). Safety of treatment options for spondyloarthritis: A narrative review. Expert Opin. Drug Saf., 17 (5), 475–486.10.1080/14740338.2018.144878529505325
- Dawson, J. K., Quah, E., Earnshaw, B., Amoasii, C., Mudawi, T., Spencer, L. G. (2021). Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review. Rheumatol. Int., 41, 1055–1064.10.1007/s00296-020-04773-4807928933515067
- Ducourau, E., Rispens, T., Samain, M., Dernis, E., Le Guilchard, F., Andras, L., Perdriger, A., Lespessailles, E., Martin, A., Cormier, G., et al. (2020). Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: A multicentric randomised trial. RMD Open, 6 (1), e001047. DOI: 10.1136/rmdopen-2019-001047.10.1136/rmdopen-2019-001047704695431958280
- Filipowicz-Sosnowska, A. (2019). Comorbidities and multimorbidity in rheumatic diseases. Reumatologia, 57 (1), 1–2.10.5114/reum.2019.83232640982730858624
- Gossec, L., Baraliakos, X., Kerschbaumer, A., de Wit, M., McInnes, I., Dougados, M., Primdahl, J., McGonagle, D. G., Aletaha, D., Balanescu, A., et al. (2020). EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann. Rheum. Dis., 79, 700–712.10.1136/annrheumdis-2020-217159728604832434812
- Hainer, R., O’Riordan, B. (2020). From virtual care to hybrid care: COVID-19 and the future of telehealth insights from the 2020 Amwell Physician and Consumer Survey. https://static.americanwell.com/app/uploads/2020/09/Amwell-2020-Physician-and-Consumer-Survey.pdf (accessed 13.06.2021).
- Hua, C., Buttgereit, F., Combe, B. (2020). Glucocorticoids in rheumatoid arthritis: Current status and future studies. RMD Open, 6 (1), e000536. DOI: 10.1136/rmdopen-2017-000536.10.1136/rmdopen-2017-000536704696831958273
- Hunter, T., Nguyen, C., Birt, J., Smith, J., Shan, M., Tan, H., Lisse, J., Isenberg, K. (2021). Pain medication and corticosteroid use in ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis in the United States: A retrospective observational sudy. Rheumatol. Ther., 8, 1371–1382.10.1007/s40744-021-00344-6838059534312825
- Isaacs, J. D., Burmester, G. R. (2020). Smart battles: Immunosuppression versus immunomodulation in the inflammatory RMDs. Ann. Rheum. Dis., 79 (8), 991–993.10.1136/annrheumdis-2020-218019739248232527869
- Jackson, L. E., Edgil, T. A., Hill, B., Owensby, J. K., Smith, C. H., Singh, J. A., Danila, M. I. (2022). Telemedicine in rheumatology care: A systematic review. Semin. Arthritis Rheum., 56, 152045. DOI: 10.1016/j.semarthrit.2022.152045.10.1016/j.semarthrit.2022.15204535843158
- Jokar, M., Jokar, M. (2018). Prevalence of inflammatory rheumatic diseases in a rheumatologic outpatient clinic: Analysis of 12626 cases. Rheumatol. Res., 3 (1), 21–27.10.22631/rr.2017.69997.1037
- Makol, A., Davis, J. M. 3rd, Crowson, C. S., Therneau, T. M., Gabriel S. E, Matteson, E. L. (2014). Time trends in glucocorticoid use in rheumatoid arthritis: Results from a population-based inception cohort, 1980–1994 versus 1995–2007. Arthritis Care Res., 66 (10), 1482–1488.10.1002/acr.22365417727924821680
- McInnes, I. B., Gravallese, E. M. (2021). Immune-mediated inflammatory disease therapeutics: past, present and future. Nat. Rev. Immunol., 13, 1–7.10.1038/s41577-021-00603-1843686734518662
- Mikuls, T. R., Johnson, S. R., Fraenkel, L., Arasaratnam, R. J., Baden, L. R., Bermas, B. L., Chatham, W., Cohen, S., Costenbader, K., Gravallese, E. M., et al. (2020). American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1. Arthritis Rheumatol., 72 (8), 1241–1251.10.1002/art.4130132349183
- Myasoedova, E., Davis, J., Matteson, E. L., Crowson, C. S. (2020). Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985–2014. Ann. Rhem. Dis., 79 (4), 440–444.10.1136/annrheumdis-2019-216694708546432066556
- Piga, M., Floris, A., Congia, M., Chessa, E., Cangemi, I., Cauli, A. (2022). Telemedicine in rheumatology: high specificity and sensitivity of follow-up virtual video consultations during COVID-19 pandemic. Rheumatology (Oxford), 61 (5),1795–1801.10.1093/rheumatology/keab632843639334352098
- Radner, H. (2016). Multimorbidity in rheumatic conditions. Wien. Klin. Wochenschr., 128 (21–22), 786–790.10.1007/s00508-016-1090-x510480927738754
- Ruderman, E. M. (2012). Overview of safety of non-biologic and biologic DMARDs, Rheumatol., 51 (6), 37–43.
- Santos-Moreno, P., Chavez-Chavez, J., Hernández-Zambrano, S. M., Rivera-Triana, D. P., Castiblanco-Montañez, R. A., Aza, A., Buitrago-Garcia, D., Villarreal, L., Rojas-Villarraga, A. (2021). Experience of tele-medicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic. Ann. Rheum. Dis., 80, e65. DOI: 10.1136/annrheumdis-2020-218165.10.1136/annrheumdis-2020-21816532586920
- Sathi, N., Chikura, B., Kaushik, V. V., Wiswell, R., Dawson, J. K. (2012). How common is methotrexate pneumonitis? A large prospective study investigates. Clin. Rheumatol., 31, 79–83.10.1007/s10067-011-1758-621638023
- Sepriano, A., Kerschbaumer, A., Smolen, J. S., van der Heijde, D., Dougados, M., van Vollenhoven, R., McInnes, I. B., Bijlsma, J. W., Burmester, G. R., de Wit, M., Falzon, L., Landewé, R. (2020). Safety of synthetic and biological DMARDs: A systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis., 79 (6), 760–770.10.1136/annrheumdis-2019-21665332033941
- Smolen, J. S., Landewé, R. B. M., Bijlsma, J. W. J., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A., van
- Vollenhoven, R. F., de Wit, M., et al. (2020). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis., 79 (6), 685–699.
- Sokka, T., Kautiainen, H., Toloza, S., Mäkinen, H., Verstappen, S. M., Lund Hetland, M., Naranjo, A., Baecklund, E., Herborn, G., Rau, R., et al. (2007). QUEST-RA: Quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann. Rheum. Dis., 66 (11), 1491–1496.10.1136/ard.2006.069252211161817412740
- Stouten, V., Pazmino, S., Verschueren, P., Mamouris, P., Westhovens, R., de Vlam, K., Bertrand, D., Van der Elst, K., Vaes, B., De Cock, D. (2021). Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study. RMD Open, 7, e001671. DOI: 10.1136/rmdopen-2021-001671.10.1136/rmdopen-2021-001671822053434158353
- Tornero-Molina, J., Sánchez-Alonso, F., Fernández-Prada, M., Bris-Ochaita, M. L., Sifuentes-Giraldo, A., Vidal-Fuentes, J. (2021). Telerheumatology during the COVID-19 pandemic. Reumatol. Clin., 18 (3), 157–163. DOI: 10.1016/j.reumae.2020.10.002.10.1016/j.reumae.2020.10.002816932334088655
- Vanhoof, J., Declerck, K., Geusens, P. (2002). Prevalence of rheumatic diseases in a rheumatological outpatient practice. Ann. Rheum. Dis., 61, 453–455.10.1136/ard.61.5.453175408111959771
- Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., Prescott, H. C. (2020). Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA, 324 (8), 782–793.10.1001/jama.2020.1283932648899
- Ziade, N., El Khoury, B., Zoghbi, M., Zoghbi, M., Merheb, G., Abi Karam, G., Mroue’, K., Messaykeh, J. (2020). Prevalence and pattern of comorbidities in chronic rheumatic and musculoskeletal diseases: The COMORD study. Sci. Rep., 10 (1), 7683. DOI:10.1038/s41598-020-64732-8.10.1038/s41598-020-64732-8720322832376850